Additionally, SMO inhibitors targeting CAFs blocked the Hedgehog signaling pathway and enhanced chemotherapy efficacy in a mouse model but demonstrated no effects in clinical trials for pancreatic ductal adenocarcinoma (PDAC) (60–62). This evidence concerns the gene SMO and pancreatic ductal adenocarcinoma.